Key Takeaways
- Revenue: $2.77 billion, beating consensus estimates of $2.62 billion by 5.7%.
- EPS: $2.50 (non-GAAP), surpassing the forecasted $2.12 by nearly 18%.
- Outlook: Full-year 2026 procedure growth guidance raised to 13.5%-15.5%.
Back
Back
Intuitive Surgical Jumps 7% After Crushing Q1 Earnings Forecasts
Intuitive Surgical Inc. (NASDAQ: ISRG) saw its stock climb over 7 percent after reporting first-quarter revenue of $2.77 billion and earnings of $2.50 per share, significantly outperforming analyst expectations.
"Q1 was a solid start to the year for Intuitive, driven by 17% total procedure growth and broad-based adoption across da Vinci and Ion, as customers continue to advance minimally invasive care," Dave Rosa, Chief Executive Officer, said on the earnings call.
The results showed strength across the board, with revenue growing 23% year-over-year. The performance was driven by a 17% increase in total procedure volume and the placement of 431 da Vinci surgical systems, up 17% from the prior year.
The strong report and upgraded forecast underscore robust demand for the company's new da Vinci 5 system. Management raised its full-year 2026 da Vinci procedure growth forecast to a range of 13.5% to 15.5% and increased its adjusted gross profit margin outlook to between 67.5% and 68.5%.
A key driver of the quarter's success was the rapid adoption of the new da Vinci 5 platform. The company placed 232 da Vinci 5 systems in Q1, accounting for more than half of total placements. Management noted that utilization for the da Vinci 5 is approximately 11% higher than the previous Xi model, contributing to a 4% increase in overall U.S. utilization. This successful launch is creating a "platform refresh wall," solidifying Intuitive's market position for the coming years.
Outside the U.S., da Vinci procedures grew 19%, led by strength in Europe, India, and Canada. However, the company continues to face challenges in Asia, citing a difficult environment in China due to domestic competition and pricing pressure, and slower growth in Japan following fewer system placements in 2025.
The company’s other platforms also showed strong momentum. The Ion endoluminal platform for lung biopsy saw procedures increase 39%, while the SP single-port platform procedures grew 68% year-over-year, driven by expansion in Korea and the U.S.
The strong earnings beat and raised guidance signal management's confidence in sustained demand, particularly for its higher-margin da Vinci 5 systems. Investors will watch the Q2 earnings release in July for continued momentum in da Vinci 5 placements and any improvement in the challenging Asian markets.
This article is for informational purposes only and does not constitute investment advice.
[1] Earnings call transcript: Intuitive Surgical Q1 2026 beats forecasts, stock reacts By Investing.com[2] Intuitive Surgical (ISRG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates[3] Intuitive Surgical Reports Another Blowout Quarter: Time to Buy the Stock?[4] Buy UnitedHealth or Intuitive Surgical Stock After Strong Q1 Results?
Features
Resources
© 2026 Finture Development Limited. All rights reserved